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The organ common-type (CT) isoenzyme of acylphosphatase is
inactivated by Woodward’s reagentK (WRK) (N-ethyl-5-phenyl-
isoxazolium-3«-sulphonate) at pH 6.0. The inactivation reaction
follows apparent pseudo first-order kinetics. The dependence of
the reciprocal of the pseudo first-order kinetic constant (k
obs
) on
the reciprocal WRK concentration reveals saturation kinetics,
suggesting that the WRK forms a reversible complex with the
enzyme before causing inactivation. Competitive inhibitors, such
as inorganic phosphate and ATP, protect the enzyme from WRK
inactivation, suggesting that this reagent acts at or near to the
enzyme active site. The reagent–enzyme adduct, which elicits a
strong absorption band with k
max
at 346 nm, was separated from
unreacted enzyme by reverse phase HPLC and the modified
protein was cleaved with endoproteinase Glu-C to produce
fragments. The HPLC fractionation gave two reagent-labelled
peptides (peak 1 and peak 2) that were analysed by ion-spray MS
INTRODUCTION
Acylphosphatase (E.C. 3.6.1.7) is an enzyme with a low M
r
(98
amino acid residues), which catalyses the hydrolysis of com-
pounds containing the carboxyphosphate bond. The enzyme acts
both on low molecular-mass compounds (metabolites such as
1,3-bisphosphoglycerate and carbamoyl phosphate and synthetic
acyl phosphates [1]), and on proteins containing phosphorylated
carboxy groups, such as Na+}K+-ATPase [2] and Ca#+-ATPase
[3], which mediate membrane ion transport. Recently, this type
of protein phosphorylation (aspartyl phosphate) has been dis-
covered in several bacterial species as well as in yeast, where one
protein of the two-component system (a system involved in
adaptation to changes in cell environment) is phosphorylated on
an aspartate residue [4,5]. Two isoenzymes of acylphosphatase
have been discovered and their amino acid sequences have been
determined [6,7]. These two isoenzymes, named the organ
common-type (CT) and muscle-type (MT), originate from two
distinct genes and elicit about 50% sequence similarity. Both are
expressed in animals in a tissue-specific manner [8,9]. Recently,
CT-isoenzyme crystals have been produced [10] and X-ray
diffraction analysis has revealed that the main fold of CT
acylphosphatase is very similar to that of the MT isoenzyme [11].
The physiological role of acylphosphatase is not yet completely
understood. However, several reports have demonstrated that
the enzyme is involved in the control of the ionic conditions in
the cell [12,13], probably acting on the aspartyl phosphate
formed during the functioning of membrane-ion pumps [14,15].
Other reports have indicated that the enzyme is involved in cell
differentiation [16–18]. In particular, a very recent report on
the differentiation of the K562 cell line, when stimulated by PMA
(which induces megakaryocytic differentiation), or by aphidicolin
Abbreviations used: WRK, Woodward’s reagent K (N-ethyl-5-phenylisoxazolium-3«-sulphonate) ; CT, common-type ; MT, muscle-type ; WT, wild-type ;
TFA, trifluoroacetic acid.
1 To whom correspondence should be addressed.
and sequenced. The former is VFFRKHTQAE (residues 20–29
of human CT acylphosphatase) and the latter IFGKVQGVF-
FRKHTQAE (residues 13–29). MS demonstrated that both
peptides are WRK adducts. A fragment ion with m}z of 1171,
which is present in the mass spectrum of peak 1, has been
identified as a WRK adduct of the peptide fragment 20–26. The
k
max
at 346 nm of WRK adduct suggests that the modified
residue is His-25. Five recombinant enzymes mutated in residues
included in the 20–29 polypeptide stretch have been produced.
Analysis of their reactivities with WRK demonstrates that His-
25 is the molecular target of the reagent as its modification causes
the inactivation of the enzyme. Since both His-25!Gln and
His-25!Phe mutants maintain high catalytic activity, we suggest
that the observed enzyme inactivation is caused by the reagent
(covalently bound to His-25), which shields the active site.
or hemin (which stimulate erythrocytic differentiation), has
demonstrated that while the MT isoform showed an average 10-
fold increase independently of the differentiating agent used,
only hemin treatment caused a similar increase in the CT isoform,
suggesting a different role for the two isoenzymes in the cell [18].
Finally, the demonstration that the tertiary structure of the
enzyme is identical with that of the RNA-binding domain of
nuclear RNA-binding proteins [19,20] and that the enzyme
possesses nucleolytic activity [21], together with the observation
that the CT isoenzyme is able to migrate into the nucleus during
apoptosis [22], all suggest that the enzyme is involved in critical
biological functions.
This paper deals with the inactivation of CT acylphosphatase
caused by Woodward’s reagent K (WRK) (N-ethyl-5-phenyl-
isoxazolium-3«-sulphonate). This reagent has been generally used
as a chemical modifier of enzyme carboxy groups. The structure
of WRK incorporates some features common to good acylphos-
phatase substrates, such as benzoyl phosphate, since it contains
an aromatic benzene ring and an anionic moiety and, therefore,
could be expected to have some affinity for the acylphosphatase
active site.
MATERIALS AND METHODS
Human CT-recombinant acylphosphatase isoenzyme was pre-
pared as described previously [23]. WRK and endoproteinase
Glu-C were purchased from Sigma. The pGEX-KT vector,
oligonucleotides and the unique restriction-site-elimination
mutagenesis kit were obtained from Pharmacia. Sequenase was
obtained from the U.S. Biochemical Co. [a-$#P]ATP (3000 Ci}
mmol) was obtained from DuPont-NEN. All other reagents were
the purest commercially available.
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Protein determination
Protein concentration was assayed using the bicinchoninic acid
method (Sigma).
Enzyme assay and kinetic parameters
Acylphosphatase activity was assayed using a continuous optical
recording with benzoyl phosphate as substrate [24]. The substrate
was dissolved in 0.1 M sodium acetate buffer, pH 5.3, and the
incubation was performed at 25 °C. The main kinetic parameters
(K
m
and V
max
) were determined by measuring the initial rates at
different substrate concentrations (ranging from 0.1–5 mM). The
experimental data were analysed using the Michaelis equation
and a non-linear fitting program (FigureP; Biosoft). Enzyme
inhibition by P
i
(a well-known competitive inhibitor of the
enzyme) was determined measuring initial hydrolysis rates at
differing substrate (range 0.1–5 mM) and P
i
(range 0.5–4 mM)
concentrations. The apparent K
m
values measured at the various
P
i
concentrations were plotted against P
i
concentration to
calculate the K
i
value. All initial rate measurements were carried
out in triplicate at least.
Reaction of CT acylphosphatase with WRK
Freshly prepared stock solutions of WRK in 1 mM HCl were
used. The modification reactions were performed at 25 °C in
0.15 Msodiumcacodylate buffer, pH 6.0. The incubationmixture
(180 ll) contained 85 lM enzyme and WRK ranging from
0.1–2.4 mM (final concentration). At different time intervals, the
reaction was quenched by the addition of 10 ll of 2.5 M sodium
acetate and the mixtures were assayed for enzyme activity. In
experiments performed with some mutated enzymes, the final
concentration of WRK was increased in order to measure
inactivation rates. Ligands (P
i
or ATP) were added before the
addition of the WRK stock solutions. The number of modified
residues per enzyme molecule was determined as follows. The
enzyme solutions were incubated in separate vials with 0–20 mM
WRK (final concentration) at 25 °C. After 2 min, the reaction
was stopped by the addition of sodium acetate (0.13 M, final
concentration). The samples (after 10 min) were applied to a
Sephadex G25 column (1 cm¬30 cm) equilibrated with 0.05 M
sodium cacodylate buffer, pH 6.0, containing 0.6 M NaCl. The
column was eluted at a flow rate of 40 ml}h, and 2 ml fractions
were collected. The void volume fractions were pooled and the
absorption spectrum was recorded. All enzyme samples treated
with WRK had an absorption band with a k
max
at 346 nm, which
was not present in the untreated samples. The levels of protein
modified by WRK were estimated by the increase in absorbance
at 340 nm (e 7000 M−"[cm−" ; [25]).
Endoproteinase Glu-C digestion and purification of peptides
Endoproteinase Glu-C digestion was performed as follows. The
enzyme [wild-type (WT) or modified, 700 lg] was dissolved in
0.1 M sodium phosphate buffer (pH 7.8)}1 M guanidinium
chloride, endoproteinase Glu-C (34 lg) was added and the
mixture was incubated at 30 °C for 16 h. The sample was dried
in a vacuum evaporator (Savant), dissolved in 20 ll of water and
applied on to a Vydac Protein and Peptide C
")
HPLC column
(4.6 mm¬250 mm, 5 lm). Peptides were eluted using a tri-
fluoroacetic acid (TFA)}acetonitrile gradient, as described in the
legend to Figure 4. The A
#"%
and A
$%'
were recorded and fractions
were collected manually.
Sequence analysis and MS
The amino-acid sequences were determined using the Milligen
Mod 6600 Protein Sequencer. Peptides were covalently immobi-
lized on poly(vinylidene difluoride)–arylamine membranes using
a carbodiimide-based attachment method, and were then applied
to the sequencer reactor.
Ion-spray mass spectra of WRK-labelled peptides in positive
ion mode were acquired on a Perkin-Elmer Sciex API III mass
spectrometer (Sciex Co., Thornhill, Ontario, Canada) using an
ion-spray voltage of 5.5 kV, an orifice voltage of 60 V and a scan
range of 500–1600 m}z.
Site-directed mutagenesis of acidic residues
Site-directed mutagenesis was performed using a unique-restric-
tion-site elimination kit according to the manufacturer’s instruc-
tions, with minor modifications to the pGEXKT-CT acylphos-
phatase construct. CT acylphosphatase cDNA was inserted into
the pGEXKT expression vector as described previously [23], and
this was used as a template for the unique-restriction-site
elimination oligonucleotide-directed mutagenesis reaction [26].
The following amino acid residues were substituted: Arg-23!
His, Lys-24!Gln, His-25!Gln, His-25!Phe and Glu-29!
Gln using five different 25-base-long synthetic oligonucleotides
to introduce single mutations, together with the ApaI restriction-
site-eliminating oligonucleotide. The mutated genes were com-
pletely sequenced using the method of Sanger [26a] to verify that
a single mutation had occurred. The expressed fusion proteins
were purified by single-step affinity chromatography using a
glutathione-linked agarose resin as described previously [23]. The
presence of a thrombin-cleavage site at the joining point of the
chimaera protein permitted the cleavage of the recombinant
enzyme from the fusion protein using purified bovine thrombin.
Thrombin cleavage was performed by incubating each fusion
protein on ice for 30 min with 1:500 (w}w) thrombin in
50 mM Tris}HCl buffer (pH 8.0)}150 mM NaCl}0.1% (w}v)
2-mercaptoethanol}2.5 mM CaCl
#
. Each cleaved CT acylphos-
phatase mutant was separated from uncleaved fusion protein by
affinity-chromatography on glutathione-linked resin.
RESULTS
CT acylphosphatase inactivation by WRK
Incubation of CT acylphosphatase with WRK at pH 6.0 and
25 °C resulted in a time- and concentration-dependent loss of
enzymic activity (Figure 1A). Since some authors have observed
the formation of reversible WRK–enzyme complexes before
covalent-bond formation [27,28], we applied the following model,
proposed by Petra [27], in order to analyse the mechanism of
acylphosphatase inactivation by WRK:
E­IY
KI
E[ IU
k
#
E®I
where, E is free enzyme; I is WRK; E[I is the enzyme–WRK
reversible complex; E–I is the enzyme–WRK covalent complex;
K
I
is the apparent E[I dissociation constant ; k
#
is the intrinsic
rate constant for covalent modification of CT acylphosphatase.
Using the method of Petra [27], we derived the following
equation:
ln
[E«]
[E
!
]
¯®k
obs
¬t
where [E«]¯ [E]­[E[I], [E
!
] is the total enzyme concentration,
and k
obs
¯k
#
}(K
I
}[I]­1). The inactivation rate can be obtained
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Figure 1 Inactivation of CT acylphosphatase by WRK
(A) WT CT acylphosphatase (85 lM, 180 ll final volume) was treated with 0.1, 0.4, 0.8, 1.6
or 2.4 mM WRK (final concentrations) at 25 °C in 0.15 M sodium cacodylate buffer, pH 6.0.
At various time intervals, aliquots were removed and assayed for residual activity. The inset
shows the effect of the competitive inhibitor Pi on the inactivation of the WT CT acylphosphatase.
The experiments were performed with 85 lM enzyme in 0.15 M sodium cacodylate buffer,
pH 6.0, in a final volume of 180 ll at 25 °C. Line 1, control ; line 2, 5 mM WRK and 100 mM
Pi ; line 3, 5 mM WRK. (B) [WRK] dependence of the pseudo first-order rate constant (kobs) for
the WT and mutant enzymes. H25F, His-25! Phe ; H25Q, His-25! Gln ; K24Q, Lys-24!
Gln ; E29Q, Glu-29! Gln.
by plotting the ln percentage of residual activity versus time (t).
Figure 1(A) shows that, at WRK concentrations in the range
0.1–2.4 mM, the inactivation reaction obeys pseudo first-order
kinetics. At higher WRK concentrations, biphasic inactivation
curves were observed (see the 5 mM WRK curve, Figure 1(A)
inset). The apparent first-order kinetic constant (k
obs
) values
relative to the different WRK concentrations were calculated
from all curves shown in Figure 1(A). The data were further
analysed with the following equation [27] :
1
k
obs
¯
K
I
k
#
[I]
­
1
k
#
Replotting 1}k
obs
, measured at various WRK concentrations
(range 0.2–2.4 mM), against the reciprocal of WRK concen-
tration, we observed saturation kinetics (the straight line fails to
pass through the origin) (Figure 1B). This finding demonstrates
Table 1 Some kinetic parameters of recombinant WT and mutated human
CT acylphosphatases
Vmax (lmol/min//mg) Km (mM) Ki (Pi) (mM)
WT 4870³89 0.14³0.01 0.58³0.03*
Arg23!His 3.6³0.1 n.d. n.d.
Lys24! Gln 2753³22 0.45³0.01 1.75³0.07*
His25! Gln 2785³17 0.49³0.03 1.96³0.05*
His25! Phe 6646³73 0.25³0.01 1.34³0.03*
Glu29! Gln 5249³65 0.13 ³0.01 0.53³0.07*
* Competitive inhibition ; n.d., not determined.
Figure 2 Stoichiometry of the modification of CT acylphosphatase by WRK
Residual activity was plotted against mol of modified residues/mol of enzyme. The enzyme
(85 lM) was treated with 0–20 mM WRK in 0.15 M sodium cacodylate buffer, pH 6.0, in a
final volume of 180 ll at 25 °C. After two min, the reaction was terminated and the protein was
separated from the reagent by Sephadex G25 chromatography. The continuous line shows the
initial enzyme inactivation caused by WRK with a single highly reactive group, with extrapolation
to zero activity. The broken line shows the inactivation caused by the reaction of WRK with
additional groups, with extrapolation to zero activity.
the formation of an enzyme–WRK reversible complex before the
modification of the covalent enzyme, which brings about in-
activation of the enzyme. Using the proposed model, we can
calculate the apparent dissociation constant and the apparent
first-order rate constant at saturation for the WT enzyme at
25 °C and pH 6.0 (K
I
¯ 0.59 mM and k
#
¯ 0.0094 s−" respect-
ively).
The influence of P
i
, a product of substrate hydrolysis which
competitively inhibits the enzyme (K
I
¯ 0.58 mM), and ATP
(K
I
¯ 63 lM, competitive inhibition) was studied. The inset of
Figure 1(A) shows that P
i
protects the enzyme from WRK-
inactivation. ATP, which is a competitive inhibitor, also protects
the enzyme from WRK inactivation (results not shown). The K
I
of 0.59 mM found for WRK indicates that the affinity of the
enzyme for WRK is very similar to that for P
i
(K
I
¯ 0.58 mM).
This is probably due to the sulphonate moiety of WRK, which
mimics the phosphate moiety of the substrate, thus interacting
with the anion binding site of the enzyme.
Stoichiometry of enzyme modification
Figure 2 shows the stoichiometry of WRK incorporation into
acylphosphatase as function of residual activity. It can be seen
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that the plot is biphasic. In the former phase (0–30% inactivation,
0–0.4 mM WRK), the experimental data fit to a straight line that
intersects the abscissa at a point corresponding to the incor-
poration of 1 mol of WRK}mol of enzyme indicating that a
single enzyme residue is involved in the inactivation. In the latter
phase (inactivation values above 30% produced by 0.5–20 mM
WRK), the experimental data fit a straight line having a different
slope. This line intersects the abscissa at a point corresponding to
the incorporation of 3 mol of WRK}mol of enzyme, suggesting
that, during this phase, two additional residues with lower
reactivity are modified by WRK. Similar results have been
observed for different enzymes in their reactions with WRK
[27–31]. We noted that the competitive inhibitor P
i
protected the
enzyme from WRK inactivation at levels of 20% residual activity
(Figure 1A, inset), suggesting that all three reactive residues are
protected.
Separation of the WRK–enzyme complex from unreacted enzyme
The acylphosphatase–WRK adduct was separated from un-
reacted enzyme by gel filtration on Sephadex G25 and reverse
phase HPLC. Experimental conditions for enzyme modification
and for adduct purification are described in the legend to Figure
3. Two peaks (peak-I and peak-II), were eluted at about 36%
acetonitrile concentration (Figure 3A). The fractions containing
these two peaks were collected, dried, redissolved in water and
their UV spectra were recorded. Peak I elicited an absorption
band at 280 nm, due mainly to the presence of protein tyrosine
and tryptophan residues (Figure 3B), and peak II produced an
additional absorption band with k
max
at 346 nm (Figure 3C).
Similar absorbance in the 340–350 nm range has been reported
for several protein–WRK adducts [27,29–38]. The stoichiometry
of WRK incorporation, measured using the method of [25], was
1.2 mol of WRK}mol of enzyme. Thus peak I is unreacted
enzyme and peak II is WRK-derivatized enzyme.
Separation of the endoproteinase Glu-C fragments, sequence and
MS analyses of WRK-labelled peptides
The upper two traces (A, B) of Figure 4 show the elution profile
of endoproteinase Glu-C peptides obtained from the native
enzyme after HPLC. The lower two traces (C, D) show the
profile of the peptides obtained from the WRK-derivatized
enzyme. The patterns differ mainly in the presence of two peaks
(peak-1 and peak-2) seen in panel D, both with absorbancies at
214 and 346 nm (the latter is the k
max
of the protein–WRK
adducts). The height of peak 1 is about twice that of peak 2.
Amino-acid-sequence analysis of peak 1 gave: VFFRKHTQAE,
while that of peak 2 gave: IFGKVQGVFFRKHTQAE. Peak 1
contained the sequence of residues 20–29, and peak 2 contained
the sequence of residues 13–29 of human CT acylphosphatase.
Figures 5(A) and 5(B) show the ion-spray mass spectra of peak
1 and peak 2 respectively. The presence of the molecular ion with
a mass of 1515.4 m}z, shown in Figure 5(A), confirms that a
single site in peptide residues 20–29 was modified by WRK (the
calculated molecular mass of the adduct is 1515.7). The mass
spectrum of peak 2 (Figure 5B) shows a major peak having a
mass of 1123.8 m}z. Since the calculated molecular mass of this
peptide adduct is 2245.6, the 1123.8 m}z peak represents the
double-charged (M+­2H)#+ ionof theWRKadductwith residues
13–29 of the acylphosphatase peptide. The molecular-ion peak
(Figure 5B, inset) was not observed, probably because its yield
was very low. Although mass and absorption spectra showed
that both peptides were WRK adducts, gaps or unusual phenyl-
thiohydantoin derivatives were not observed in the Edman
sequencing. This is probably due to the instability of the WRK
Figure 3 Separation of WRK-modified from non-modified CT acyl-
phosphatase by HPLC
(A) The enzyme (5 mg) was treated with 0.2 mM WRK in 0.15 M sodium cacodylate buffer,
pH 6.0, at 25 °C in a final volume of 3.6 ml. When the residual activity had decreased to approx.
70%, the reaction was stopped by the addition of 150 ll of 2.5 M sodium acetate and the
enzyme was separated from the reagents by gel filtration on a Sephadex G25 column
(2.5¬30 cm) equilibrated with 0.05 M sodium cacodylate (pH 6.0)/0.6 M NaCl, and eluted at
a flow rate of 120 ml/h ; 2.5 ml fractions were collected. The protein contained in the void
volume was applied to a reverse-phase HPLC column (4.6¬75 mm, 5 lm; Altex ULTRAPORE
RPSC) equilibrated with 10 mM TFA in water. After washing with this solvent for 10 min at a
flow rate of 0.8 ml/min, a 10 mM TFA in acetonitrile (solvent A) gradient was applied
(0–10 min, 0% solvent A, followed by 0–70% solvent A over 60 min). (B) UV absorption
spectrum of peak-I (non-modified enzyme) isolated in (A). (C) UV absorption spectrum of peak-
II (WRK-modified enzyme) isolated in (A).
adduct in the strong acidic environment of the solid-phase
Edman chemistry.
Both peptides contained a single acidic residue, i.e. Glu-29. As
several published papers have indicated acidic residues as targets
of WRK in proteins [27,29,30,34–36,38], we have considered the
possibility that this residue could be the target of WRK in the
inactivation of CT acylphosphatase. We observed that endo-
proteinase Glu-C easily produced the cleavage of the Glu-29–
Gly-30 peptide bond, indicating that this acidic residue contains
its c-carboxy group in a free form, thus excluding the possibility
that this residue is the target of WRK in CT acylphosphatase
inactivation. In order to identify the actual WRK target residue
in acylphosphatase, we considered the report of Llamas et al.
[39]. This very valuable research showed that, in aqueous
solutions, WRK rapidly produces a keto ketenimine which reacts
easily with several chemical groups of protein side-chains. They
observed that the reaction rates of WRK with model compounds
containing imidazole, thiol, amino, phenoxide, carboxylate
and carboxy groups are all pH-dependent. Taking the results
obtained by these authors into consideration, we would expect
imidazole to be more reactive than carboxyl and primary amino
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Figure 4 HPLC resolution of endoproteinase Glu-C digests
The two upper traces (A, B) are the elution profile of the unmodified enzyme. The two lower
traces (C, D) are those of the WRK-modified enzyme (the modified enzyme contained about
1 mol of WRK/mol of enzyme). Both peak-I and peak-II enzymes (700 lg of each, prepared
as described in the legend to Figure 3) were digested with endoproteinase Glu-C as described
in the Materials and methods section. The digests were applied on to a reverse-phase HPLC
column (4.6¬250 mm, 5 lm; Peptide and Protein C18, Vydac) equilibrated with 10 mM TFA
in water at a flow rate of 0.72 ml/min. A 10mM TFA/acetonitrile gradient (0–27%) was applied
over 60 min. The elution of WRK adducts was monitored at A346. The WRK-labelled peptides
(peak-1 and peak-2) were collected and dried under vacuum.
groups, since we performed the acylphosphatase–WRK inac-
tivation experiments at pH 6.0 [39]. In addition, the k
max
at
346 nm of the band present in the spectrum of the enzyme–WRK
adduct (Figure 3C) is very close to that observed by these authors
for the imidazole–WRK adducts (342 nm for conjugated acid
and 348.5 nm for conjugated base, pK«
a
¯ 4.5). The enol ester
produced in the reaction of WRK with a carboxy group should
have a k
max
close to 267 nm, and the primary amine–WRK
adduct should have a k
max
at 246.5 nm (conjugated acid) and
319 nm (conjugated base, the pK«
a
of the methylamine–WRK
adduct is 6.81) [39]. Considering that CT acylphosphatase does
not contain cysteine residues, and that neither peptide residues
13–29 nor peptide residues 20–29 contains tyrosine, the target
residue(s) of WRK involved in enzyme inactivation should be
restricted to Lys-16, Lys-24 and His-25. Figure 5(A) shows the
direct ion-spray mass spectrum of peak 1. It can be seen that it
contains mass peaks at 1515.4 m}z (M+­H)+, 1262.8 m}z
(M+®WRK), 758.6 m}z (M+­2H)#+ and 632.1 m}z [(M+
®WRK)­2H]#+. These values fit very well with the WRK
adduct of the sequence 20–29 of human CT acylphosphatase, as
discussed above. This spectrum also contains two additional
mass peaks (1171.1 and 917.1 m}z) which produce information
about the WRK target residue. They are fragments of pep-
tide residues 20–29 that fit with the sequence of the free peptide
residues 20–26 (H
#
N-Val-Phe-Phe-Arg-Lys-His-Thr-CO) (cal-
culated molecular mass, 917.1) and with that of the WRK adduct
of the same peptide (calculated mass 1171.4). These fragments
contain both Lys-24 and His-25, the amino and imidazole groups
Figure 5 Mass spectra of WRK-labelled endoproteinase Glu-C peptides
Ion-spray mass spectra of (A) peak 1 and (B) peak 2.
respectively which could have reacted with WRK. Nevertheless,
we believe that the residue modified by WRK is His-25, since the
k
max
of the enzyme–WRK adduct agrees more closely with an
imidazole–WRK adduct than with a lysine–WRK adduct [39].
Site-directed mutagenesis
The site-directed mutagenesis of a number of residues included in
the WRK-labelled peptide named peak 1 (Figure 4) was per-
formed. The WT human CT acylphosphatase and Arg-23!His,
Lys-24!Gln, His-25!Gln, His-25!Phe, and Glu-29!Gln
mutant genes were prepared as described in the Materials and
methods section. The major kinetic properties of these enzymes
are shown in Table 1. We note that only the Arg-23!His
mutant shows a dramatic loss of activity, the V
max
was only
0.07% of that of the WT enzyme. Similar results, obtained with
three Arg-23 mutants of the MT isoenzyme indicated that this is
an essential residue, which is probably involved in substrate
binding [40]. Since both MT and organ CT isoenzymes have
similar folding [11], we suppose that Arg-23 has a similar role in
the catalytic mechanisms of acylphosphatase isoenzymes. Al-
though the K
m
and the K
I
(P
i
) values of Lys-24!Gln, His-25!
Gln and His-25!Phe mutants are increased (by 2–3 times), they
maintain relatively high V
max
values (the V
max
value of the His-25
!Phe mutant is 35% higher than that of the WT enzyme),
which suggests that these charged residues do not have important
roles in the catalytic pathway of the enzyme. Similar conclusions
can be deduced from the kinetic parameters of the Glu-29!Gln
mutant.
We have tested the ability of WRK to inactivate WT and
mutant enzymes in order to reveal the residue involved in
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WRK–enzyme inactivation. All enzymes were incubated with
various WRK concentrations and enzyme activity was monitored
for 2 min. Figure 1(B) shows 1}k
obs
against 1}[WRK] with Glu-
29!Gln, His-25!Gln, His-25!Phe and Lys-24!Gln mu-
tant enzymes and of the WT enzyme (the Arg-23!His mutant
was not tested as it had negligible activity). It can be seen that the
mutant enzymes agree with the model applied to the WT enzyme,
since they show saturation kinetics. We also found that the
reactivity of both His-25!Gln and His-25!Phe mutants with
WRK was dramatically decreased. In fact, we found that at
1.6 mM WRK (pH 6.0, 25 °C) the reactivity of the His-25!Gln
mutant was 7 times lower than that of the WT enzyme (k
obs
,
7.0¬10−$[s−" and 1.0¬10−$[s−" for the WT enzyme and for the
His-25!Gln mutant enzyme respectively) ; after 2 min incu-
bation, the His-25!Phe mutant retained almost 100% activity
but the activity of the WT enzyme was approx. 44%, suggesting
that the replacement of His-25 with phenylalanine renders the
enzyme almost fully protected against the effects of WRK.
Although WRK is able to modify a total of three enzyme
residues (see Figure 2), our findings strongly suggest that His-25
is the most reactive and is the initial target of WRK in the
chemical modification of CT acylphosphatase. His-25 is not a
conserved residue; all other known acylphosphatases contain
tyrosine residues in position 25 of the sequence. The kinetic
parameters elicited by the His-25!Phe mutant, which is more
active that the WT enzyme, indicate that the presence of a
nucleophilic residue in this position is not necessary for catalysis.
DISCUSSION
We have shown that the plot of inactivation of human CT
acylphosphatase activity against increasing levels of modified
enzyme follows a straight line up to 70% residual activity
(Figure 2). The extrapolation of this line intercepts the abscissa
(100% inactivation) at a point which indicates WRK-labelling of
a single enzyme residue per enzyme molecule. At levels of
inactivation greater than 30% we observed that the slope of the
graph changed, suggesting that increasing enzyme modification
by WRK is accompanied by the reaction of two additional
residues with reactivities lower than that of the first residue.
The main conclusion of this work is that, at relatively low
concentrations, WRK interacts specifically with the human CT
acylphosphatase isoenzyme and causes enzyme inactivation. The
specificity of the WRK–enzyme interaction is probably due to
the sulphonate moiety of WRK (a substrate mimetic group),
which interacts initially with the anion binding site of the enzyme
forming a reversible complex [the dissociation constant (K
I
) of
this complex is very close to that of the enzyme–P
i
complex]. The
formation of this complex favours the reaction of the WRK keto
ketenimine moiety with the nucleophilic His-25 forming an
enamine derivative (the absorption band with k
max
at 346 nm of
the WRK–enzyme adduct supports the reaction of WRK with an
imidazole group [39]). Competitive inhibitors (P
i
and ATP),
which interact with the anion-binding site of the enzyme, protect
the enzyme from inactivation since they hinder the binding of
WRK to this site. We emphasize that His-25!Gln and His-25
!Phe mutants maintain high catalytic activities (Table 1),
indicating that His-25, although located near to the active site (it
is close to the active-site Arg-23 residue), plays no important role
in the catalysis. Thus the observed enzyme inactivation by WRK
is probably due to steric hindrance by the reagent, which shields
the active site. Alternatively, the covalently-linked WRK may
alter acylphosphatase folding locally leading to enzyme in-
activation. This latter hypothesis could explain the pronounced
reduction in WRK reactivities of both His-25 mutants ; in fact,
the initial reaction of His-25 with WRK may cause the trans-
position of the two additional reactive enzyme residues to the
solvent (and then to the reagent). Although these residues appear
to be protected from WRK attack by P
i
, we think that their
participation in the enzyme active site is uncertain. Both mutants
of His-25, which have high activity levels and clearly contain the
two additional residues modified by WRK, are very resistant to
WRK inactivation (the His-25!Phe mutant is almost totally
resistant to attack by WRK), suggesting that the two additional
residues have no important catalytic roles.
Using protein chemistry to study the initial phase of WRK–
enzyme inactivation, we demonstrated that a single enzyme
residue was modified. In fact, we purified the WRK adduct from
a mixture which contained 70% residual enzyme activity and we
isolated two WRK-labelled peptides (each containing a sole
WRK molecule), which originated from the same polypeptide
stretch. No other WRK-labelled peak was found in the enzymic
fingerprint of the modified protein (Figure 4). In addition, we
found that the stoichiometry of the WRK–enzyme adduct,
separated from unreacted protein by reverse-phase HPLC, is
about 1 mol of WRK}mol of enzyme.
The modification of His-25 during the initial reaction of WRK
with CT acylphosphatase is clearly demonstrated by the pro-
nounced lower WRK reactivity of both His-25 mutants and was
supported by spectroscopic and MS data.
It was generally thought that the inactivation of enzymes by
WRK is caused by the chemical modification of aspartic or
glutamic acid residues involved in the active site. On the other
hand, our findings clearly demonstrate that the chemical modifi-
cation of CT acylphosphatase by WRK has no carboxyl targets.
About ten years ago, Llamas et al. [39] suggested that the
reaction of WRK with the nucleophilic side chains (such as
cysteine, histidine, lysine, glutamic and aspartic acid) of several
proteins could easily occur, especially at pH values greater than
5.0. On the contrary, several authors have taken the fact that
they are inactivated by WRK as evidence for the involvement of
acidic amino acids in the active site of several enzymes
[27,29,30,34–36,38]. We think that the inactivation of an enzyme
by WRK may not be taken as prima facie evidence for the
presence of an essential carboxy group. In fact, the absorption
peak with k
max
in the 340–350 nm region, frequently observed in
protein–WRK adducts [25,27,29–38], could arise from the re-
action of WRK with protein imidazole, thiolate and phenoxide
nucleophiles. This is true, since the k
max
of the carboxylate enol
esters is expected to be centred close to 267 nm [39]. The reaction
of WRK with the carboxy group is certainly more specific at pH
values in the range 3–5, since the reactivity of carboxy groups in
this pH range is greater than that of other nucleophiles [39]. A
recent paper, which describes the WRK-inactivation of Escher-
ichia coli threonine dehydrogenase, demonstrates that two histi-
dines His-105 and His-205, which are not in the catalytic site, and
the essential active-site Cys-38 form WRK adducts [37].
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